Sodium Bicarbonate News and Research

RSS
NIAID-funded Phase I trial to evaluate two related candidate vaccines against shigellosis

NIAID-funded Phase I trial to evaluate two related candidate vaccines against shigellosis

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Santarus launches UCERIS for induction of remission in patients with ulcerative colitis

Diet high in fruits and vegetables may help protect kidneys of patients with CKD

Diet high in fruits and vegetables may help protect kidneys of patients with CKD

Researchers investigate acidity in solid tumors to determine if pH levels play a role in cell invasion

Researchers investigate acidity in solid tumors to determine if pH levels play a role in cell invasion

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

FDA approves Santarus’ UCERIS for induction of remission in patients with ulcerative colitis

Positive results from Santarus and Pharming’s RUCONEST Phase III trial on HAE

Positive results from Santarus and Pharming’s RUCONEST Phase III trial on HAE

Simple test confirms correct catheter placement

Simple test confirms correct catheter placement

Lower pH reduces ability of ASL to kill bacteria in CF airways

Lower pH reduces ability of ASL to kill bacteria in CF airways

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

PLC's RenalGuard REMEDIAL II trial against CIN presented at ACC.11

American Regent initiates voluntary recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%

American Regent initiates voluntary recall of Sodium Bicarbonate Injection, USP 7.5% and 8.4%

Daily dose of baking soda affects kidney function: Study

Daily dose of baking soda affects kidney function: Study

Perrigo files NDA with FDA for generic Zegerid OTC

Perrigo files NDA with FDA for generic Zegerid OTC

Perrigo fourth-quarter fiscal 2010 net sales up 22%

Perrigo fourth-quarter fiscal 2010 net sales up 22%

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Par Pharmaceutical second-quarter total net revenues decrease 37% to $255.5 million

Prasco to sell and distribute authorized generic version of ZEGERID capsules

Prasco to sell and distribute authorized generic version of ZEGERID capsules

Prasco commences shipments of generic prescription ZEGERID Capsules

Prasco commences shipments of generic prescription ZEGERID Capsules

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Perrigo acquires rights to Novel Laboratories' pending ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Perrigo acquires rights to ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

Perrigo acquires rights to ANDA for HalfLytely and Bisacodyl Tablets Bowel Prep Kit

ZEGERID OTC capsules offer more rapid acid reduction than Prevacid- 24HR delayed-release capsules

ZEGERID OTC capsules offer more rapid acid reduction than Prevacid- 24HR delayed-release capsules

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010

Par Pharmaceutical reports total revenues of $291.9 million for first-quarter 2010